Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index

Talley, Nicholas J.; Haque, Md. Enamul; Wyeth, John; Stace, Nigel H.; Tytgat, G. N. J.; Stanghellini, Vincenzo; Holtmann, Gerald; Verlinden, M.; Jones, Michael

doi:10.1046/j.1365-2036.1999.00445.x

Cited by 202 publications

(184 citation statements)

References 54 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…Secondary outcome variables were the course of overall changes in individual dyspeptic symptoms during treatment, the sum score of the patient's selfrating of intensity of each dyspeptic symptom, the sum score of differences to baseline and improvement of health-related quality of life as assessed using the Nepean Dyspepsia Index (NDI), 19,20 and overall assessments of efficacy by patient and investigator. The intensity of dyspeptic symptoms was rated on a fourpoint Lickert scale from no symptoms (0 points) to severe symptoms (3 points).…”

Section: Methodsmentioning

confidence: 99%

Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six‐week placebo‐controlled, double‐blind, multicentre trial

Holtmann

Adam

Haag

et al. 2003

Aliment Pharmacol Ther

126

View full text Add to dashboard Cite

SUMMARYBackground: This study aimed to assess the efficacy of artichoke leaf extract (ALE) in the treatment of patients with functional dyspepsia (FD). Methods: In a double-blind, randomized controlled trial (RCT), 247 patients with functional dyspepsia were recruited and treated with either a commercial ALE preparation (2 · 320 mg plant extract t.d.s.) or a placebo. The primary efficacy variable was the sum score of the patient's weekly rating of the overall change in dyspeptic symptoms (four-point scale). Secondary variables were the scores of each dyspeptic symptom and the quality of life (QOL) as assessed by the Nepean Dyspepsia Index (NDI).

show abstract

Section: Methodsmentioning

confidence: 99%

Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six‐week placebo‐controlled, double‐blind, multicentre trial

Holtmann

Adam

Haag

et al. 2003

Aliment Pharmacol Ther

126

View full text Add to dashboard Cite

show abstract

“…Disorders-Quality of Life (PAGI-QOL) 242 • Functional Digestive Disorders Quality of Life Questionnaire (FDDQL) 243 • Nepean Dyspepsia Index (NDI) 227 • Impact on day-to-day activity scale 224 • Glasgow Dyspepsia Severity Score 244 • Quality of Life in Reflux and Dyspepsia Questionnaire (QOLRAD) 245 • Gastrointestinal Quality of Life Index (GIQLI) 246 QOL, quality of life. …”

Section: Box 5 | Qol Instruments For Functional Dyspepsiamentioning

confidence: 99%

Functional dyspepsia

Enck¹,

Azpiroz

Boeckxstaens

et al. 2017

Nat Rev Dis Primers

253

247

View full text Add to dashboard Cite

| Functional dyspepsia is one of the most prevalent functional gastrointestinal disorders. Functional dyspepsia comprises three subtypes with presumed different pathophysiology and aetiology: postprandial distress syndrome (PDS), epigastric pain syndrome (EPS) and a subtype with overlapping PDS and EPS features. Functional dyspepsia symptoms can be caused by disturbed gastric motility (for example, inadequate fundic accommodation or delayed gastric emptying), gastric sensation (for example, sensations associated with hypersensitivity to gas and bloating) or gastric and duodenal inflammation. A genetic predisposition is probable but less evident than in other functional gastrointestinal disorders, such as irritable bowel syndrome (IBS). Psychiatric comorbidity and psychopathological state and trait characteristics could also play a part, although they are not specific to functional dyspepsia and are less pronounced than in IBS. Possible differential diagnoses include Helicobacter pylori infection and peptic ulceration. Pharmacological therapy is mostly based on the subtype of functional dyspepsia, such as prokinetic and fundus-relaxing drugs for PDS and acid-suppressive drugs for EPS, whereas centrally active neuromodulators and herbal drugs play a minor part. Psychotherapy is effective only in a small subset of patients, whereas quality of life can be severely affected in nearly all patients. Future therapies might include novel compounds that attempt to treat the underlying gastric and duodenal inflammation. NATURE REVIEWS | DISEASE PRIMERS VOLUME 3 | ARTICLE NUMBER 17081 | 1 PRIMER © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .standard therapy for gastro -oesophageal reflux disease. Paediatric dyspeptic symptoms are being addressed in a separate classification effort 10 . This Primer covers functional dyspepsia in adults only, although we sporadically refer to paediatric functional dyspepsia when similarities exist. EpidemiologyThe population prevalence of functional dyspepsia is quite variable across the globe, with overall high numbers (10-40%) in Western countries and low numbers (5-30%) in Asia, independent of the respective functional dyspepsia definitions 11 . A large-scale health and nutrition survey from France 12 (which involved >35,000 people) identified that 15% of individuals had suspected functional dyspepsia, 28% had irritable bowel syndrome (IBS) and 6% had both. The population of patients who are affected by both IBS and functional dyspepsia has been reported to range between 10% and 27% in previous studies 13 and to approach 30% in popu lation samples; it could be even higher in specific populations 14,15 . This observation has given rise to the term 'overlap syndrome' (REF. 13), which calls into question the sensitivity and specificity of the Rome criteria, at least for IBS and functional dyspepsia. This argument is also supported by the observation that patients with functional dyspepsia m...

show abstract

“…16,17 The major dyspeptic symptoms were assessed using a four item symptom questionnaire, which scores postprandial abdominal fullness or discomfort, early satiety, epigastric pain and burning on a four point scale. A higher score represents more severe dyspepsia complaints.…”

Section: Instrumentsmentioning

confidence: 99%

Brain-based Correlations Between Psychological Factors and Functional Dyspepsia

Nan

Liu

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/AimsIncreasing evidence shows involvement of psychological disorders in functional dyspepsia (FD), but how psychological factors exert their influences upon FD remains largely unclear. The purpose of the present study was to explore the brain-based correlations of psychological factors and FD. MethodsBased on Fluorine-18-deoxyglucose positron emission tomography-computed tomography, the altered cerebral glycometabolism was investigated in 40 FD patients compared with 20 healthy controls during resting state using statistical parametric mapping software. ResultsFD patients exhibited increased glucose metabolism in multiple regions relative to controls (P < 0.001, family-wise error corrected). After controlling for the dyspeptic symptoms, increased aberrations persisted within the insula, anterior cingulate cortex (ACC), middle cingulate cortex (MCC) and middle frontal cortex (midFC), which was related to anxiety and depression score. Interestingly, FD patients without anxiety/depression symptoms also showed increased glycometabolism within the insula, ACC, MCC and midFC. Moreover, FD patients with anxiety/depression symptoms exhibited more significant hypermetabolism within the above 4 sites compared with patients without anxiety/depression symptoms. 2012CB518501, 2014CB543203 and 2011CB707700, the National Natural Science Foundation of China under Grant No. 81471737, 81471811, 81471738, 81473602, 81227901, 81271644, 30930112, 81101036, 81371530, 81101108, 31200837, and 81371530

show abstract

Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index

Abstract: The Nepean Dyspepsia Index is a reliable and valid disease-specific index for dyspepsia, measuring symptoms and health-related quality of life.

Cited by 202 publications

References 54 publications

Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six‐week placebo‐controlled, double‐blind, multicentre trial

Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six‐week placebo‐controlled, double‐blind, multicentre trial

Functional dyspepsia

Brain-based Correlations Between Psychological Factors and Functional Dyspepsia

Contact Info

Product

Resources

About